News + Font Resize -

Vyome appoints Dr Ranjan Pai as board of directors & Dr Richard Buchta as sr VP of R&D
Our Bureau, Mumbai | Tuesday, December 2, 2014, 17:15 Hrs  [IST]

Vyome Biosciences, an innovation-driven dermatology company focused on hard to treat and refractory dermatology indications, announced that MD and CEO of Manipal Education & Medical Group, Dr Ranjan Pai, has joined its board of directors. Dr Pai’s venture firm Aarin Capital is an investor in Vyome.

The company also appointed Dr Richard Buchta, formerly head of GlaxoSmithKline’s dermatology unit Stiefel Laboratories in Australia, as senior vice-president of R&D.


Dr Pai is recognized as one of India’s top corporate leaders. As Vyome scales operations and prepares to enter the commercialization phase, his addition adds tremendous strategic experience to the board. The globalization and expansion of the Manipal Education and Medical Group through his strategic vision is an experience that will serve Vyome in good stead as the company looks abroad for development and licensing opportunities, said NVenkat, co-founder & CEO.



“Vyome is a proving to be a serious innovative play in the life sciences industry, and holds a special place in Aarin’s portfolio. I am personally looking forward to work more closely with the rest of the board, Shiladitya, Venkat and the rest of their team as the Company breaks new ground in markets both in India and abroad,” said Dr Ranjan Pai, chairman of Manipal Education & Medical Group and Founding Partner at Aarin Capital.


Dr Buchta brings rich specialist experience with numerous patent applications and multiple IND filings in dermatology to Vyome’s senior management team, and this will multiply the company’s capabilities as we enter the regulatory filing stages for our pharmaceutical programs. Vyome is geared up to press ahead on,” added N Venkat,


“I am delighted that Dr Pai is getting involved closely with Vyome at this stage – he has a stellar reputation and his extensive experience in the healthcare industry will be of tremendous value to the Company.  Dr Buchta’s engagement will be a tremendous asset too. I am confident that Vyome will go from strength to strength in the coming year,” said Dr. Raghunath Mashelkar, Padma Vibhushan recipient and chairman of Vyome’s board of directors.

Post Your Comment

 

Enquiry Form